First National Advisers’s Edwards Lifesciences EW Stock Holding History

First National Advisers’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.88M	Sell	36,012 -5,467	-13%	-$451K	0.42%	62
2025 Q4	$3.54M	Sell	41,479 -669	-2%	-$54.9K	0.49%	54
2025 Q3	$3.28M	Buy	42,148 +664	+2%	+$51.9K	0.44%	65
2025 Q2	$3.24M	Buy	41,484 +9,644	+30%	+$719K	0.48%	60
2025 Q1	$2.31M	Sell	31,840 -9,950	-24%	-$712K	0.37%	84
2024 Q4	$3.09M	Buy	41,790 +215	+0.5%	+$15K	0.5%	58
2024 Q3	$2.74M	Buy	41,575 +2,158	+5%	+$157K	0.44%	76
2024 Q2	$3.64M	Buy	39,417 +9,641	+32%	+$854K	0.67%	44
2024 Q1	$2.75M	Buy	29,776 +591	+2%	+$49.6K	0.62%	48
2023 Q4	$2.23M	Buy	29,185 +8,296	+40%	+$577K	0.64%	53
2023 Q3	$1.45M	Buy	20,889 +9,361	+81%	+$752K	0.65%	51
2023 Q2	$1.09M	Buy	11,528 +3,965	+52%	+$345K	1%	28
2023 Q1	$626K	Buy	7,563 +211	+3%	+$16.6K	0.71%	54
2022 Q4	$549K	Buy	7,352 +756	+11%	+$58.3K	0.7%	57
2022 Q3	$545K	Buy	6,596 +1,920	+41%	+$185K	0.81%	45
2022 Q2	$445K	Buy	+4,676	New	+$484K	0.92%	42

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

First National Advisers's EW Position: Q1 2026 in Review

First National Advisers reduced its Edwards Lifesciences (EW) stake by 13% in Q1 2026, selling an estimated $451K and leaving 36,012 shares worth $2.88M. The position accounts for 0.42% of the portfolio, ranked #62.

First National Advisers first reported a position in EW in Q2 2022 and has held it in 16 quarters since. The position peaked at $3.64M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

First National Advisers held 36,012 shares of Edwards Lifesciences worth $2.88M as of Q1 2026.
First National Advisers sold 5,467 Edwards Lifesciences shares in Q1 2026, an estimated $451K.
Edwards Lifesciences made up 0.42% of First National Advisers's portfolio in Q1 2026, its #62 holding.
First National Advisers first reported a position in Edwards Lifesciences in Q2 2022 and has held it in 16 quarters since.
First National Advisers's Edwards Lifesciences position peaked at $3.64M in Q2 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on First National Advisers's 13F filing for Q1 2026, filed 8 May 2026.